Policy & Regulation
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
21 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted Priority Rev...
Circio files new patent application for circVec gene therapy platform
21 May 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) announced on Thursday that it has filed a patent application with the European Patent Office covering a novel genetic element designed...
BioMarin Pharmaceutical meets primary endpoint in Phase 3 study of VOXZOGO in children with hypochondroplasia
21 May 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Wednesday that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO (vosoritide) in ...
Hyundai Bioscience says XAFTY available for Ebola and Hantavirus treatment
21 May 2026 - South Korea-based biotechnology company Hyundai Bioscience announced on Wednesday that XAFTY has a strong likelihood of being able to treat Ebola and Hantavirus due to its low IC50 (50% ...
4basebio secures clinical supply agreement for Phase II immunotherapy trial
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to prov...
FDA approves MEKanistic Therapeutics' IND for MTX-531
20 May 2026 - Biotechnology company MEKanistic Therapeutics announced on Tuesday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug application for MTX-531, its le...